Galena Biopharma Reports Third Quarter 2014 Results

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Galena Biopharma Reports Third Quarter 2014 Results
  • Clinical programs advance on multiple fronts, with trial initiation, trial enrollment, data and IP milestones achieved and anticipated
  • Commercial strategy reinforced with product acquisition and upcoming commercial launch
    • Abstral ® (fentanyl) sublingual tablet net revenue was $1.6 million in Q3 2014 and $6.1 million to date this year, with reiterated guidance of $8-$10 million for the full year 2014
    • Zuplenz ® (ondansetron) Oral Soluble Film U.S. rights licensed; launch expected in Q1 2015
  • Conference call scheduled for 5:00 pm E.T. today with details below

PORTLAND, Ore., Nov. 3, 2014 (GLOBE NEWSWIRE) -- Galena Biopharma, Inc. (Nasdaq: GALE ), a biopharmaceutical company developing and commercializing innovative, targeted oncology treatments that address major unmet medical needs to advance cancer care, today reported its financial results for the quarter ended September 30, 2014 and provided a business update.

"The company continues to make excellent progress on our clinical programs, and we continue to build our commercial franchise," said Mark W. Schwartz, Ph.D., President and Chief Executive Officer. "I believe we have turned the corner on the corporate challenges we faced this year, and we are fully focused on the progress of NeuVax ™ and its portfolio of clinical trials, our development pipeline and our commercial programs including the upcoming launch of Zuplenz ® . Over the next six months, we will report results from the ongoing trials with GALE-301 and GALE-401, and our NeuVax platform will expand with the initiation of two new trials plus the completion of enrollment in our pivotal, Phase 3 PRESENT study. The launch of Zuplenz in Q1 2015 enhances our commercialization efforts and we believe we will see significant sales growth for that business line in 2015."

Galena will host a conference call today at 2:00 p.m. P.T./5:00 p.m. E.T. to discuss financial and business results. The call can be accessed by dialing (844) 825-4413 toll-free in the U.S., or (973) 638-3403 for participants outside the U.S. The Conference ID number is: 23451769. The conference call will also be webcast live and available under the Investors section/Events and Presentations on the Company's website at www.galenabiopharma.com . The archived webcast replay will be available on the Company's website for 90 days.

Financial Highlights

Net revenue for the third quarter of 2014 was $1.6 million compared to $1.2 million for the third quarter of 2013, an increase of 25%. Net revenue for the nine months ended September 30, 2014 was $6.1 million. The third quarter of 2013 was the first quarter that the company generated net revenue.

Operating loss for the three months ended September 30, 2014 was $13.2 million, including $1.3 million in stock-based compensation charges, compared to $6.9 million, including $0.5 million in stock-based compensation charges, for the three months ended September 30, 2013.

Galena also incurs non-cash income and expense related to changes in the fair value estimates of the Company's warrant liabilities. Non-cash income related to the change in warrant values for the three months ended September 30, 2014 was $6.7 million compared to non-cash expense of $1.6 million for the three months ended September 30, 2013.

Net loss for the three months ended September 30, 2014 was $6.2 million, or $0.05 per basic and diluted share, compared to a net loss of $9.3 million, or $0.11 per basic and diluted share, for the three months ended September 30, 2013.

As of September 30, 2014, Galena had cash and cash equivalents of $24.6 million, compared with $47.8 million as of December 31, 2013.

Business Highlights

  • Announced NeuVax ™ (nelipepimut-S) Phase 3 PRESENT Trial enrollment status. Galena provided the current enrollment status for the Company's Phase 3 PRESENT ( P revention of R ecurrence in E arly- S tage, Node-Positive Breast Cancer with Low-to-Intermediate HER2 E xpression with NeuVax T reatment) clinical trial. As of September 22, 2014, 533 of the 700 patients required by the clinical trial protocol had been treated. The Company expects to treat 700 patients by the end of January 2015 with the intention to over-enroll the study, targeting the end of Q1, 2015 to close enrollment.
     
  • Significantly Expanded the NeuVax Intellectual Property Position with Notice of Allowances for Three Important Patents
    • Patent will cover the use of NeuVax to prevent recurrence of any HER2/neu expressing tumor having a fluorescence in situ hybridization (FISH) rating of less than about 2.0 as a stand-alone therapy or in combination with an adjuvant and/or other agents. Currently there are no approved HER2-directed therapies for patients who express lower levels of HER2, or less than 2.0 by the FISH testing scale. Importantly, this NeuVax patent provides Galena with coverage for any tumor expressing low-to-intermediate levels of HER2.  The patent, which has now issued, will expire in 2028, not including any patent term extensions.
    • Patent To Cover the Use of NeuVax in Combination With Herceptin ® (trastuzumab; Genentech/Roche) for treating patients having any HER2/neu expressing cancer.  The allowed claims of this patent will cover all HER2/neu expressing cancer types and patient populations. Once issued, the patent will expire in 2026, not including any patent term extensions.
    • Improvement patent in Japan will cover the use of NeuVax alone or in combination with other agents to prevent recurrence of any breast cancer tumor expressing low-to-intermediate (Immunohistochemistry (IHC) 1+ or 2+ or FISH less than about 2.0) levels of HER2. Once issued, the patent will expire in 2027, not including any patent term extensions.
       
  • Initiated the Phase 2 Clinical Trial for GALE-401 (Anagrelide Controlled Release). The study will treat patients with elevated platelet counts in myeloproliferative neoplasms (MPNs) including essential thrombocythemia (ET). The Phase 2 trial is an open-label, single-arm, multicenter study of GALE-401 in approximately 20 patients with MPN-related thrombocytosis. The goals of the study are to confirm the platelet-lowering activity of GALE-401 in patients with MPNs, to assess safety and tolerability, and to measure blood levels of the drug. The primary efficacy endpoint will be the proportion of subjects who achieve a complete or partial platelet response for at least four weeks during the first six months of treatment. Based on discussions with the U.S. Food and Drug Administration (FDA) and pending a successful development program, Galena would pursue approval via the 505(b)(2) regulatory pathway.
     
  • Appointed Mark W. Schwartz, PhD as President and Chief Executive Officer and member of the Board of Directors.  Dr. Schwartz was previously Galena's Executive Vice President and Chief Operating Officer where he worked across all of the company's programs, oversaw the initiation of the commercialization efforts, and also managed intellectual property efforts, acquisitions, and partnerships. Dr. Schwartz brings more than 30 years of experience in the biotechnology and life science industry and joined the Company following Galena's acquisition of Apthera, Inc. where he served as the company's President and CEO. Prior to Apthera, Dr. Schwartz served as President and CEO of Bayhill Therapeutics where he completed a successful partnership with Genentech around one of its compounds. Previously, he served as President and CEO of Calyx Therapeutics. Earlier in his career, Dr. Schwartz held a range of positions in R&D, marketing, sales, business development and executive management at Trega BioSciences, Incyte Genomics, Synteni, Tripos, Applied Biosystems and DuPont Diagnostics. Dr. Schwartz is currently on the advisory board for BayBio, a Director of Targazyme Pharmaceuticals, and is on the faculty of San Jose State University in the Masters of Biotechnology Program. He is also a former Board member of the Biotechnology Industry Association. Dr. Schwartz received his Bachelor of Arts in Chemistry from Grinnell College and his Ph.D. in Chemistry from Arizona State University.
     
  • Licensed the U.S. Rights for Zuplenz ® (ondansetron) Oral Soluble Film.  Zuplenz is approved by the FDA in adult patients for the prevention of highly and moderately emetogenic chemotherapy-induced nausea and vomiting (CINV), radiotherapy-induced nausea and vomiting (RINV), and post-operative nausea and vomiting (PONV).  Zuplenz is also approved in pediatric patients for moderately emetogenic CINV. Zuplenz is a rapidly dissolving, oral soluble film that dissolves on the tongue in less than thirty seconds and eliminates the burden of swallowing pills during periods of emesis and in cases of oral irritation, potentially increasing patient adherence. Galena expects to launch Zuplenz in the first quarter 2015.
GALENA BIOPHARMA, INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(Amounts in thousands, except share and per share data)
(Unaudited)
         
  Three Months Ended September 30, Nine Months Ended September 30,
  2014 2013 2014 2013
Net revenue  $ 1,620  $ 1,170  $ 6,124  $ 1,170
Costs and expenses:        
Cost of revenue (excluding amortization of certain acquired intangible assets) 247 258 925 258
Research and development 7,243 3,633 22,082 13,990
Selling, general, and administrative 7,268 4,129 23,698 8,369
Amortization of certain acquired intangible assets 70 43 259 43
Total costs and expenses 14,828 8,063 46,964 22,660
Operating loss (13,208) (6,893) (40,840) (21,490)
Non-operating income (expense):        
Change in fair value of warrants potentially settleable in cash 6,735 (1,614) 13,174 (7,135)
Interest income (expense), net (297) (314) (925) (495)
Other income (expense) 597 693 (59) 881
Total non-operating income (expense), net 7,035 (1,235) 12,190 (6,749)
Loss before income taxes (6,173) (8,128) (28,650) (28,239)
Income tax benefit — 1,159 — (62)
Net loss  $ (6,173)  $ (9,287)  $ (28,650)  $ (28,177)
Net loss per common share:        
Basic and diluted net loss per share  $ (0.05)  $ (0.11)  $ (0.24)  $ (0.33)
Weighted-average common shares outstanding: basic and diluted 119,038,656 87,319,450 117,767,791 84,678,612
 
GALENA BIOPHARMA, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
(Amounts in thousands)
     
  September 30, 2014
(Unaudited)
December 31, 2013
ASSETS    
Current assets:    
Cash and cash equivalents  $ 24,647  $ 47,787
Restricted cash 200 200
Accounts receivable 1,435 3,683
Inventories 450 386
Prepaid expenses 1,789 1,399
Total current assets 28,521 53,455
Equipment and furnishings, net 589 665
In-process research and development 12,864 12,864
Abstral rights, net 14,714 14,979
Zuplenz rights 7,663 —
GALE-401 rights 9,155 —
Goodwill 5,898 5,898
Deposits and other assets 88 115
Total assets  $ 79,492  $ 87,976
LIABILITIES AND STOCKHOLDERS' EQUITY    
Current liabilities:    
Accounts payable  $ 3,360  $ 2,660
Accrued expenses and other current liabilities 15,292 8,667
Current maturities of capital lease obligations 6 6
Fair value of warrants potentially settleable in cash 8,765 48,965
Current portion of long-term debt 4,163 2,149
Total current liabilities 31,586 62,447
Capital lease obligations, net of current maturities 17 26
Deferred tax liability 5,053 5,053
Contingent purchase price consideration, net of current portion 6,880 6,821
Long-term debt, net of current portion 5,097 7,743
Total liabilities 48,633 82,090
Total stockholders' equity 30,859 5,886
Total liabilities and stockholders' equity  $ 79,492  $ 87,976

About Galena Biopharma

Galena Biopharma, Inc. (Nasdaq: GALE ) is a biopharmaceutical company developing and commercializing innovative, targeted oncology therapeutics that address major medical needs across the full spectrum of cancer care.  Galena's development portfolio ranges from mid- to late-stage clinical assets, including a robust immunotherapy program led by NeuVax ™ (nelipepimut-S) currently in an international, Phase 3 clinical trial. The Company's commercial drugs include Abstral ® (fentanyl) Sublingual Tablets and Zuplenz ® (ondansetron) Oral Soluble Film. Collectively, Galena's clinical and commercial strategy focuses on identifying and advancing therapeutic opportunities to improve cancer care, from direct treatment of the disease to the reduction of its debilitating side-effects. For more information visit www.galenabiopharma.com .

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about our 2014 revenue from the sale of Abstral ® , our planned launch of Zuplenz ® , the issuance of patents, and the progress of development of Galena's product candidates, including patient enrollment in our clinical trials. These forward-looking statements are subject to a number of risks, uncertainties and assumptions, including those identified under "Risk Factors" in Galena's Annual Report on Form 10-K for the year ended December 31, 2013 and most recent Quarterly Reports on Form 10-Q filed with the SEC. Actual results may differ materially from those contemplated by these forward-looking statements. Galena does not undertake to update any of these forward-looking statements to reflect a change in its views or events or circumstances that occur after the date of this press release.

NeuVax ™ is a trademark of Galena Biopharma, Inc. All other trademarks are the property of their respective owners.

Remy Bernarda VP, Marketing & Communications (503) 405-8258

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Avelo Tests Loyalty Math With WeSalute Fare Discounts

Updated Category News Views 287

Airline discounts can look like generosity until the load factor starts talking back. Avelo Airlines has joined WeSalute with fare discounts for active-duty military members, veterans, first responders, nurses, medical professionals, public servants, teachers and eligible family members. It is a sensible move for a young carrier built around smaller airports and lower...

Continue Reading
Autoliv's Omni Safety Award Is a Promising Early Signal

Updated Category News Views 68

Reclined car seats are becoming a real engineering headache, not some showroom gimmick, and Autoliv has put a marker down with Omni Safety™. The company received 2026 Automotive News PACE Pilot recognition for the system, which tackles occupant protection when people are sitting farther back than conventional vehicle safety designs assumed. That matters because...

Continue Reading
Cambrian Turns Dairy Wastewater Into Long-Term Gas

Updated Category News Views 15

A Wisconsin dairy plant just traded lagoon duty for a 20-year service arrangement, and that is more consequential than the usual shiny renewable-gas headline. Cambrian Innovation says it has commissioned and is operating a wastewater treatment and resource recovery system that handles roughly 280,000 gallons a day. That works out to about 102 million gallons annually, a...

Continue Reading
Trilith Holiday Tour Blends Film Access and Giving

Updated Category News Views 71

Snow machines, trolley rides, and a mental-health subsidy are sharing the same stage in Fayetteville this holiday season. That is an unusual mix, but it fits Trilith Foundation’s stated mission better than another generic lights-and-cocoa event ever could. From Nov. 21 through Dec. 31, the Foundation is turning its guided Trilith Studios tour into a seasonal experience...

Continue Reading
LG Channels UAE Push Tests the Free Streaming Model

Updated Category News Views 102

A television's idle screen is turning into contested real estate in the UAE. LG Channels is adding programming from Rakuten TV, Stingray and Red Bull TV to its free, ad-supported service, and that matters for more than somebody hunting a movie after dinner. This is a practical push to make webOS-powered screens more useful, more frequently used and, eventually, more...

Continue Reading
TYYY Liquidation Leaves Holders With a Tight Exit Window

Updated Category News Views 210

A fund can vanish faster than investors can read the fine print, and TYYY is doing exactly that. Exchange Traded Concepts has approved the closure and liquidation of the xETFs TSLA Daily Income ETF, with the fund expected to cease operations and distribute cash on or about November 20, 2026. This is not a debate about whether holders should love or hate Tesla. The product...

Continue Reading
Leqembi’s Real-World Data Gives BioArctic More Weight

Updated Category News Views 56

A Harder Look at Treatment Staying Power Alzheimer’s drug data rarely arrive without a thicket of caveats, and that is exactly why this Leqembi update deserves a calm read rather than a victory lap. BioArctic’s partner Eisai presented a three-year real-world analysis at CTAD 2026 covering 560 early Alzheimer’s patients across 13 U.S. sites. The headline is striking:...

Continue Reading
ELEGOO's Formnext Push Tests a Broader 3D Ambition

Updated Category News Views 180

Frankfurt’s show floor is where product promises meet some very unforgiving eyeballs. ELEGOO arrived at Formnext 2026 with more than a refreshed machine or two: it is laying out a wider bet across resin printing, FDM printing, and 3D scanning. That matters because the company is no longer presenting itself as merely a supplier of affordable creator hardware. It wants to...

Continue Reading
Wealth Forum Puts AI and Tokenisation Before Private Wealth

Updated Category News Views 63

Private wealth is about to get squeezed from three directions at once: younger heirs, smarter machines and assets that do not fit neatly in the old family-office binder. That is the real backdrop to the Future of Wealth Forum, a new GFTN and Luxembourg House of Financial Technology partnership slated for Luxembourg City on September 27-29, 2027. It is early days,...

Continue Reading
CD Rates Offer Stillness as Stocks and Gold Wobble

Updated Category News Views 164

November has delivered the sort of tape that makes a supposedly diversified portfolio feel like a leaky boat. Stocks fell sharply, gold slid to a one-year low after record highs as recently as January, and Treasuries have not provided the dependable ballast many investors expected. When inflation worries and federal-debt concerns shove yields higher, bond prices can drop...

Continue Reading

Top 5 Most Recently Viewed Articles

Embracing Harmony and Cooperation in Today's World

Updated Category News Views 99

Understanding the Essence of Hehe Culture The concept of "Hehe" in Chinese culture symbolizes harmony, peace, and cooperation, deeply embedded in the collective mindset. This philosophy, with roots extending over thousands of years, emphasizes living in balance not only with one another but also with nature and oneself. The teachings of Hehe are particularly significant...

Continue Reading
Current Trends in Mortgage Rates and Home Buying Activity

Updated Category News Views 184

The average rate for a 30-year fixed-rate mortgage dropped to 6.08% in 2024, hitting its lowest point in two years. This slight decrease from 6.09% the previous week caught the eye of potential home buyers and homeowners considering refinancing. In contrast, the average rate for a 15-year mortgage ticked up by a single basis point to reach 5.16%. These small fluctuations...

Continue Reading
Mueller Water Products Engages at 2024 Baird Industrial Conference

Updated Category News Views 195

Mueller Water Products to Engage in the Baird Industrial Conference Mueller Water Products, Inc. (NYSE: MWA), headquartered in Atlanta, is set to participate in the Baird 2024 Global Industrial Conference. This prestigious event will take place in a vibrant city known for its industrial drive and innovation. Mueller’s management team is looking forward to sharing...

Continue Reading
SANY Showcases Advanced Eco-Friendly Solutions at bauma

Updated Category News Views 389

SANY Showcases Advanced Eco-Friendly Solutions at bauma The 34th bauma, recognized as the world's leading trade fair for construction machinery, recently wrapped up in Munich. This year's theme was "The World of Efficiency, Your Partner to Create the Best", and SANY Group, in collaboration with Putzmeister, put forth an impressive display of cutting-edge technology and...

Continue Reading
Orbit International Corp Completes $1 Million Power Supply Order

Updated Category News Views 182

Orbit International Corp Secures Major Follow-On Order Orbit International Corp. (OTCID Basic Market: ORBT), a prominent player in electronic manufacturing and software solutions, has announced the receipt of a new order valued at approximately $1,000,000. This order, secured by its Orbit Power Group (OPG), pertains to a commercial power supply that is utilized in...

Continue Reading